FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
12 | LEBRIKIZUMAB FOR PAEDIATRIC PATIENTS AGED ≥6 MONTHS WITH MODERATE-TO-SEVERE AD: PHASE 3 ADORABLE-1 WEEK-16 RESULTS L. Stingeni1, L. Eichenfield2, J. Ornelas3, V. Prajapati4, C. Yang5, A. Tanaka6, S. Weidinger7, C. Flohr8, E. Swanson9, L. Martin10, S. Daveiga11, R. Gontijo Lima11, H. Elmaraghy11, E. Pierce11, P. Sen11, G. Gallo11, M. Piruzeli11, A. Larkin11, M. Grau12, Y. Mihaylov12, A. Paller13 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Departments of Dermatology and Pediatrics, University of California San Diego School of Medicine, La Jolla, California, US; 3Department of Dermatology, Integrative Skin Science and Research, Sacramento, California, US; 4Dermatology Research Institute, Skin Health & Wellness Centre, Probity Medical Research, and University of Calgary, Calgary, CA; 5Chang Gung University College of Medicine, Taoyuan, TW; 6Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, JP; 7Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, DE; 8Department of Dermatology and Population Health Sciences, King’s College London, London, UK; 9Ada West Dermatology, St Luke's Children's Hospital, Idaho, US; 10School of Clinical Medicine, UNSW Sydney & Dermatology Department, Sydney Children’s Hospital, Sydney AU; 11Eli Lilly and Company, Indianapolis, Indiana,US; 12Almirall R&D, S.A., Barcelona, ES; 13Dermatology and Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, US
196PDF: 44 -
29 | The extracellular vesicle potential for the early detection of resistance to immunotherapy in melanoma patients Cristina Catoni1, Cristina Poggiana1, Alessandro Francesco Piazza1, Jacopo Pigozzo2, Luisa Piccin2, Chiara Menin1, Stefania Pellegrini1, Valentina Salizzato2, Paolo Del Fiore4, Simone Mocellin3|4, Vanna Chiarion-Sileni2, Valentina Guarneri2|3, Antonio Rosato1|3, Maria Chiara Scaini1 | 1Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua; 2Medical Oncology 2, Veneto Institute of Oncology, IOV-IRCCS, Padua; 3Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua; 4Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
372 -
Deep mycosis mimicking cutaneous squamous cell carcinoma
1420PDF: 664HTML: 98 -
47 | RECURRENCE DEFINES PROGNOSIS IN THICK MELANOMA: A LONG-TERM SINGLE-CENTER EXPERIENCE S. Apa1, P. Del Fiore2, C. Trevisiol2, G. Madeo3, N. Romagnolo4, F. Cassalia2, A. Acciardi2, S. Mocellin2|3, M. Alaibac4 | 1Department of Medicine (DIMED), School of Medicine, University of Padova, Italy; 2Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Italy; 3Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, Italy; 4Dermatology Unit, Department of Medicine, University of Padova, Italy
81PDF: 32 -
Treatment modalities of necrobiosis lipoidica: a concise systematic review
3045PDF: 1932Suppl. Table: 462HTML: 503 -
02 | Melanoma training in primary care: comparing traditional teaching with telemedicine-enhanced education. A review Giorgia Ravaglia1, Edoardo Mora2, Debora Cantagalli3, Serena Magi4, Laura Mazzoni4, Matelda Medri4, Cesare Massone5, Davide Melandri6, Federica Zamagni7, Ines Zanna8, Gianluca Pistore9, Saverio Caini8, Salvatore Amato10, Vincenzo De Giorgi11, Pietro Quaglino12, Maria Antonietta Pizzichetta13|14, Giovanni Luigi Tripepi15, Sofia Spagnolini1, Ignazio Stanganelli1|4 | 1Dermatology Resident Training Program, Department of Medicine and Surgery, University of Parma, Parma; 2Dermatology Unit, Ospedale S. Anna, Como; 3Primary Care Resident Training program, Ausl Bologna, Bologna; 4Skin Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST Meldola, Forlì-Cesena; 5Dermatology Unit, Ospedali Galliera, Genova; 6Dermatology Unit, AUSL Romagna and University of Bologna, Cesena. 7Registro Tumori della Regione Emilia Romagna, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST Meldola, Forlì-Cesena; 8Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, ISPRO, Florence; 9Clinical Epidemiology Unit, Istituto Dermopatico dell’Immacolata - IRCCS, Rome; 10Associazione Dermatologi Ospedalieri Italiani, ADOI, Sicilia and Teledermatology working group, Palermo; 11Dermatology, Department of Health Sciences, University of Florence, Florence; 12Dermatologic Clinic, Department of Medical Sciences, University of Turin, Torino; 13Department of Dermatology, University of Trieste, Trieste; 14Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano, CRO, IRCCS, Aviano; 15CNR-IFC, Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension, Reggio Calabria, Italy.
501 -
Granular cell dermatofibroma: a potential diagnostic pitfall
1089PDF: 587HTML: 168 -
Oral warty dyskeratoma: An unusual presentation
1316PDF: 604HTML: 287 -
-
Assessment effect of breast milk on diaper dermatitis
3262PDF: 1363HTML: 463 -
11 | EFFICACY AND SAFETY OF LEBRIKIZUMAB IS MAINTAINED UP TO 4 YEARS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: FIRST YEAR OF ADLONG LONG-TERM EXTENSION TRIAL L. Stingeni1, S. Weidinger2, A. Irvine3, D. Thaçi4, J. Szepietowski5, T. Biedermann6, H. Agell7, Y. Mihaylov7, B. Kostov7, R. Coll7, W. Romero8, K. Reich9 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; 3Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; 4Institute and Comprehensive Center for Inflammatory Medicine at the University of Lübeck, Lübeck, Germany; 5Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wrocław University of Science and Technology, Wrocław, Poland; 6Department of Dermatology and Allergy, Technical University of Munich, School of Medicine and Health, Munich, Germany; 7Almirall S.A., Barcelona, Spain; 8Eli Lilly and Company, Indianapolis, IN, USA; 9Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
113PDF: 49 -
28 | Efficacy and toxicity outcomes with doublet immunotherapy in metastatic melanoma: the real-world REALIPINIVO study Miriam Forte1, Francesco Caraglia1, Silvana Cozzolino1, Antonino Colloca1, Alfonso Esposito1, Maria Cristina Giugliano1, Eleonora Cioli1, Marcella Scala2, Francesca Sparano5, Maria Chiara Sergi3, Teresa Del Giudice4, Immacolata Paciolla6, Luigi Formisano2, Stefania Napolitano1, Antonio Maria Grimaldi6, Paolo Antonio Ascierto5, Fortunato Ciardiello1, Teresa Troiani1, Vincenzo De Falco1 | 1Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples; 2Department of Clinical Medicine and Surgery, Federico Il University, Naples; 3Unità Operativa Complessa di Oncologia Medica, Ospedale "Mons. A.R. Dimiccoli", Barletta; 4Nuclear Medicine Unit, "Mater Domini" University Hospital, Catanzaro; 5Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Napoli; 6Medical Oncology Unit AORN "San Pio", Benevento, Italy.
447
